Ibio Inc (IBIO)

NYSE
Currency in USD
3.4300
-0.1700(-4.72%)
Closed
After Hours
3.4384+0.0084(+0.2449%)
IBIO Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Fair Value
Day's Range
3.22003.6600
52 wk Range
1.05004.9800
Key Statistics
Edit
Prev. Close
3.6
Open
3.55
Day's Range
3.22-3.66
52 wk Range
1.05-4.98
Volume
340.45K
Average Volume (3m)
185.63K
1-Year Change
172.22%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IBIO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
4.7800
Upside
+39.36%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Ibio Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Compare IBIO to Peers and Sector

Metrics to compare
IBIO
Peers
Sector
Relationship
P/E Ratio
0.0x−3.3x−0.7x
PEG Ratio
0.00−0.080.00
Price/Book
0.0x2.3x2.6x
Price / LTM Sales
0.0x58.5x3.1x
Upside (Analyst Target)
0.0%444.6%47.6%
Fair Value Upside
Unlock28.3%7.7%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.7800
(+39.36% Upside)

Earnings

Latest Release
May 15, 2023
EPS / Forecast
-0.48 / -7.20
Revenue / Forecast
-- / 200.00K
EPS Revisions
Last 90 days

People Also Watch

4.030
TRVG
-4.28%
0.3552
NXU
+0.00%
2.700
IZEA
0.00%
0.541
VERU
+3.81%
1.8541
COCP
-0.54%

FAQ

What Is the Ibio (IBIO) Stock Price Today?

The Ibio stock price today is 3.43

What Stock Exchange Does Ibio Trade On?

Ibio is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Ibio?

The stock symbol for Ibio is "IBIO."

What Is the Ibio Market Cap?

As of today, Ibio market cap is 33.87M.

What is Ibio Earnings Per Share?

The Ibio EPS is -2.57.

From a Technical Analysis Perspective, Is IBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.